UROTHELIAL CARCINOMA

This study tests whether a combination of two drugs (disitamab vedotin and pembrolizumab) works better than standard chemotherapy for people with advanced bladder cancer that has spread. About 412 participants will be randomly assigned to receive either the new combo or chemo. Th…

This study tests whether adding the immunotherapy drug tislelizumab to standard chemotherapy helps people with advanced bladder cancer live longer. About 420 adults who have not had prior treatment for their advanced cancer will receive either tislelizumab or a placebo, along wit…

This study compares two different ways of giving the immunotherapy drug atezolizumab together with standard chemotherapy (gemcitabine and cisplatin) for people with advanced bladder cancer that has spread. The goal is to see which schedule works better at shrinking tumors. 32 adu…

This study tests two immunotherapy drugs, nivolumab and urelumab, given before bladder removal surgery for patients with muscle-invasive bladder cancer who cannot or choose not to have chemotherapy. The goal is to see if adding urelumab boosts the immune response against the tumo…

This study tests an experimental drug called INBRX-106, given alone or with the immunotherapy pembrolizumab (Keytruda), in people with advanced solid tumors (like lung, head and neck, melanoma, stomach, kidney, or bladder cancer) that have stopped responding to standard treatment…

This study tests a new antibody drug, acasunlimab, in people with advanced solid tumors that have not responded to standard treatments. The first part checks safety and finds the best dose, while the second part tests how well it works alone or with other cancer drugs. About 429 …

This early-stage study tests the safety of combining two drugs, avelumab and AVB-S6-500, in adults with advanced bladder cancer that has spread or cannot be removed by surgery. Participants must have already tried at least one standard chemotherapy. The goal is to see if the comb…

This early-stage trial tests an experimental drug called IMP321, which aims to boost the immune system's ability to fight cancer. It is given in new ways, such as direct injection into tumors or into the abdomen, and combined with other cancer treatments. The study includes 83 ad…

This study tests a drug called erdafitinib, which targets specific genetic changes in cancer cells, for people with advanced bladder cancer that has spread. About 125 participants will receive erdafitinib alone or with other treatments to see if it shrinks tumors and how safe it …

This study tests a new drug called TYRA300 in people with advanced bladder cancer or other solid tumors that have a specific gene change (FGFR3). The goal is to find a safe dose and see if the drug can shrink tumors. About 310 adults whose cancer has not responded to standard tre…

This early-phase study tests whether a new immune cell therapy, called memory-like natural killer (NK) cells, can be safely given to people with advanced kidney or bladder cancers. The treatment involves collecting a patient's own immune cells, boosting them with special proteins…

This study tests whether the immunotherapy drug pembrolizumab can shrink muscle-invasive bladder cancer enough to avoid removing the bladder. About 46 adults with localized bladder cancer will receive pembrolizumab before standard treatments. Those whose cancer completely respond…

This early-phase trial tests a new treatment for people with a high-risk bladder cancer that hasn't responded to standard therapy. Doctors take immune cells from the patient's own tumor, grow them in a lab, and put them back into the bladder. The goal is to see if this approach i…

This study is for people with advanced solid tumors (like lung, bladder, or skin cancer) that have stopped responding to standard immunotherapy drugs called PD-1/PD-L1 inhibitors. Researchers are testing a new combination of immune-boosting drugs to see if they can shrink tumors …

This study tests a new drug combination (BGB-A445 plus tislelizumab) in people with advanced bladder, kidney, or skin cancer that has spread. The goal is to see if the treatment can shrink tumors and how safe it is. About 113 participants will receive the drugs, which aim to boos…

This study tests a new treatment called cretostimogene grenadenorepvec, a virus that targets cancer cells, to see if it can keep intermediate-risk bladder cancer from returning after surgery. About 367 people will be randomly assigned to receive the virus or just be watched. The …

This early-phase study tests the safety and best dose of the drug veliparib when given with standard chemotherapy (carboplatin and paclitaxel) in adults with advanced solid tumors that also have liver or kidney dysfunction. The goal is to find out how the body processes the drugs…

This study tests a drug called UGN-102 for people with a low-grade, intermediate-risk type of bladder cancer that hasn't spread into the muscle. The goal is to see if this drug can destroy the cancer without needing surgery. About 240 participants received the drug, and researche…

This study tests a new drug called UGN-103, which is placed directly into the bladder, to treat a type of low-grade bladder cancer that hasn't spread into the muscle. About 99 people with this cancer at intermediate risk of coming back will receive the treatment. The main goal is…

This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy helps shrink bladder cancer that has spread to nearby lymph nodes. About 60 adults with this type of cancer will be randomly assigned to receive either chemo alone or chemo plus durvalumab.…

This study tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy (gemcitabine and cisplatin) is safe and effective for people with advanced or muscle-invasive bladder cancer. About 54 adults with good overall health are taking part. The goal is to see …

This study tests whether giving the drug enfortumab vedotin less often can still control advanced bladder cancer while reducing side effects. About 60 adults with cancer that has spread will receive the drug alone or with pembrolizumab. The goal is to see if a de-escalated schedu…

This study was designed for people with muscle-invasive bladder cancer who cannot receive the standard chemotherapy drug cisplatin. It aimed to test whether the targeted therapy erdafitinib, alone or combined with the immunotherapy atezolizumab, could shrink tumors before surgery…

This early-stage trial was designed to test a combination of three drugs (N-803, pembrolizumab, and enfortumab vedotin) in people with advanced bladder cancer that had not been treated before. The goal was to see if the combination was safe and could help control the cancer. Howe…

This study tests a new drug called SKB264 in people with advanced solid tumors (like lung, breast, or ovarian cancer) that have not improved with standard treatments. The goal is to find the best dose and see if it can shrink tumors. About 1,410 participants will receive the drug…

This early-phase trial studies whether adding the immunotherapy drug pembrolizumab to standard chemotherapy can help people with rare, aggressive small cell or neuroendocrine cancers of the bladder or prostate. About 15 participants with cancer that has spread will receive the co…

This study tests a combination of three drugs (pemetrexed, etrumadenant, and zimberelimab) in 10 adults with advanced bladder cancer that has a specific genetic change called MTAP deficiency. All participants had prior immunotherapy. The goal is to see if the combo shrinks tumors…

This study collects blood, tissue, and urine samples from 589 adults with different types of kidney or urinary tract tumors, plus healthy controls. Researchers use advanced DNA sequencing to find unique markers (methylated DNA) that could help detect these cancers earlier. The go…

This early-phase study tests a special PET scan (using 18F-fluciclovine) to see if it can more accurately show how far muscle-invasive bladder cancer has spread, compared to standard CT or MRI scans. Sixteen adults with bladder cancer scheduled for bladder removal surgery will ge…

This study compares two CT scan methods (single-bolus vs. split-bolus) to see which one better detects urinary tract cancers. About 352 adults aged 40 and older who have blood in their urine or a history of urinary cancer will be randomly assigned to one of the two scan types. Th…

This early-phase study tests a new imaging tracer called 68Ga-FAPI-46 in 26 people with various cancers. The tracer targets cells around tumors, helping PET scans show where cancer is located. Researchers want to see how well the tracer works and compare it to standard imaging. T…

This study looks at tumor samples from 15 people with kidney or bladder cancer whose cancer came back after immunotherapy. Researchers compare the genes and structure of the original tumor with the new growth to find clues about why the cancer became resistant. The goal is to bet…

This study follows over 2,700 patients with bladder, lung, or liver cancer who are receiving the drug atezolizumab as part of their normal care. Researchers are tracking how long patients live and how well the drug controls their cancer outside of a controlled trial setting. The …

This study reviews medical records of 360 Japanese patients with advanced bladder cancer who received avelumab as a maintenance treatment after initial chemotherapy. The goal is to understand patient characteristics, treatment patterns, and outcomes like survival and tumor respon…